{"id":51347,"date":"2020-11-23T18:32:08","date_gmt":"2020-11-23T16:32:08","guid":{"rendered":"http:\/\/infois.ro\/?p=51347"},"modified":"2020-11-23T18:32:08","modified_gmt":"2020-11-23T16:32:08","slug":"medicamentul-minune-impotriva-covid-19-inclus-in-schema-de-tratament-a-pacientilor-de-la-spitalul-de-boli-infectioase-din-iasi","status":"publish","type":"post","link":"https:\/\/infois.ro\/?p=51347","title":{"rendered":"\u201eMedicamentul-minune\u201d \u00eempotriva COVID-19, inclus \u00een schema de tratament a pacien\u0163ilor de la Spitalul de Boli Infec\u0163ioase din Ia\u015fi"},"content":{"rendered":"<p><a href=\"http:\/\/infois.ro\/wp-content\/uploads\/2020\/04\/carmen-dorobat-2.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft  wp-image-47264\" src=\"http:\/\/infois.ro\/wp-content\/uploads\/2020\/04\/carmen-dorobat-2.jpg\" alt=\"\" width=\"333\" height=\"242\" srcset=\"https:\/\/infois.ro\/wp-content\/uploads\/2020\/04\/carmen-dorobat-2.jpg 640w, https:\/\/infois.ro\/wp-content\/uploads\/2020\/04\/carmen-dorobat-2-300x218.jpg 300w\" sizes=\"(max-width: 333px) 100vw, 333px\" \/><\/a><\/p>\n<p style=\"text-align: justify;\">Spitalul de Boli Infec\u0163ioase din Ia\u015fi a realizat un studiu clinic privind folosirea medicamentului Regeneron \u00een tratarea formelor u\u015foare \u015fi medii ale bolii COVID-19, rezultatele \u00eenregistrate \u00een acest sens fiind mai mult dec\u00e2t \u00eencurajatoare. Astfel, dup\u0103 cum a declarat dr. Carmen Dorob\u0103\u0163, managerul Spitalului de Boli Infec\u0163ioase din Ia\u015fi, \u00een urma tratamentului cu acest medicament, starea de s\u0103n\u0103tate a celor trei pacien\u0163i participan\u0163i la studiu s-a \u00eembun\u0103t\u0103\u0163it vizibil, un lucru foarte important reprezent\u00e2ndu-l \u015fi faptul c\u0103 utilizarea medicamentului nu a condus la reac\u0163ii adverse. \u201eEste vorba, mai precis, despre un concentrat de anticorpi, care poart\u0103 denumirea de Regeneron. De fapt, este o solu\u0163ie care cuprinde doi anticorpi, care \u201e\u00eembrac\u0103\u201d ca o m\u0103nu\u015f\u0103 virusul, \u00eempiedic\u00e2ndu-l s\u0103 se a\u015feze pe celul\u0103, la locul receptor, \u015fi, prin urmare, s\u0103 se multiplice. \u00cen cadrul acestui studiu clinic am folosit medicamentul la trei pacien\u0163i. Din declara\u0163iile acestora a reie\u015fit c\u0103 utilizarea medicamentului nu a avut niciun efect secundar, iar starea general\u0103 de s\u0103n\u0103tate a pacien\u0163ior s-a \u00eembun\u0103t\u0103\u0163it\u201d, a declarat dr. Carmen Dorob\u0103\u0163. Managerul Spitalului de Boli Infec\u0163ioase din Ia\u015fi sus\u0163ine c\u0103 aprobarea, \u00een urm\u0103 cu c\u00e2teva zile, de c\u0103tre Agen\u0163ia Alimentelor \u015fi Medicamentelor din SUA (FDA) a acestui medicament \u00een tratamentul formelor u\u015foare \u015fi medii de COVID-19 reprezint\u0103 un important pas \u00eenainte \u015fi pentru acceptarea acestuia \u00een Europa. \u201eEste foarte important s\u0103 avem un astfel de tratament pentru forme u\u015foare \u015fi medii de COVID-19, cu at\u00e2t mai mult cu c\u00e2t \u00een lipsa acestuia, boala se poate agrava, iar pacientul poate deveni dependent de oxigen sau, \u015fi mai grav, este nevoie ca el s\u0103 fie tratat \u00een Sec\u0163ia de Anestezie \u015fi Terapie Intensiv\u0103. De aceea, prezen\u0163a acestui medicament \u015fi \u00een Europa este a\u015fteptat\u0103 cu mare interes\u201d, a mai spus medicul ie\u015fean. Regeneron este un \u201ecocktail\u201d de doi anticorpi puternici, despre care se crede c\u0103 stimuleaz\u0103 r\u0103spunsul imun la virusul SARS-CoV-2. Tratamentul experimental cu acest medicament s-a folosit, \u00een premier\u0103, \u00een SUA, fiindu-i administrat inclusiv pre\u015fedintelui Donald Trump, atunci c\u00e2nd acesta a anun\u0163at, \u00een var\u0103, c\u0103 a fost infectat cu noul tip de coronavirus.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Spitalul de Boli Infec\u0163ioase din Ia\u015fi a realizat un studiu clinic privind folosirea medicamentului Regeneron&#8230; <a class=\"meta-more\" href=\"https:\/\/infois.ro\/?p=51347\">more <span class=\"meta-nav\">&raquo;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":47264,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[41,24],"tags":[74,13025,13876,40,250,13875,5958],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/infois.ro\/index.php?rest_route=\/wp\/v2\/posts\/51347"}],"collection":[{"href":"https:\/\/infois.ro\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/infois.ro\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/infois.ro\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/infois.ro\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=51347"}],"version-history":[{"count":1,"href":"https:\/\/infois.ro\/index.php?rest_route=\/wp\/v2\/posts\/51347\/revisions"}],"predecessor-version":[{"id":51348,"href":"https:\/\/infois.ro\/index.php?rest_route=\/wp\/v2\/posts\/51347\/revisions\/51348"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/infois.ro\/index.php?rest_route=\/wp\/v2\/media\/47264"}],"wp:attachment":[{"href":"https:\/\/infois.ro\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=51347"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/infois.ro\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=51347"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/infois.ro\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=51347"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}